Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Many women who survived childhood cancer do not undergo recommended breast cancer screening

Despite recommendations and being at an increased risk of breast cancer, most young women who were treated with chest radiation for a childhood cancer do not undergo appropriate mammography screening, according to a study in the January 28 issue of JAMA, the Journal of the American Medical Association.

29 Jan 2009

Helicobacter pylori can multiply in autophagic vesicles

Helicobacter pylori , a Gram-negative, flagellated, microaerophilic bacterium, can selectively colonize in the human stomach.

29 Jan 2009

Medarex announces allowance of IND application for antibody-drug conjugate, MDX-1203

Medarex, Inc. has announced the allowance of an investigational new drug (IND) application filed with the U.S. Food & Drug Administration (FDA) for MDX-1203, the Company's first Antibody-Drug Conjugate (ADC) candidate generated from its proprietary technology.

29 Jan 2009

Virotherapy treatment kills prostate cancer cells

A new study appearing in The Prostate has found that certain measles virus vaccine strain derivatives, including a strain known as MV-CEA, may prove to be an effective treatment for patients with advanced prostate cancer.

21 Jan 2009

Researchers show how anthracycline class of chemotherapeutics block blood vessel growth, slow cancer spread

Researchers at the Johns Hopkins University School of Medicine have discovered how a whole class of commonly used chemotherapy drugs can block cancer growth.

21 Jan 2009

Breakthrough in treatment of cancers and infectious diseases

Dr. André Veillette, a researcher at the Institut de recherches cliniques de Montréal (IRCM), and his team led by postdoctoral fellow Dr. Mario-Ernesto Cruz-Munoz, will publish in the upcoming issue of the prestigious journal Nature Immunology of Nature Publishing Group.

19 Jan 2009

Cell Therapeutics targeting potential Zevalin label expansion,

In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) reviewed 2009 targeted milestones and 2008 accomplishments.

15 Jan 2009

Researchers find genes that fuse in cancer

Using new technologies that make it easier to sequence the human genome, researchers at the University of Michigan Comprehensive Cancer Center have identified a series of genes that become fused when their chromosomes trade places with each other.

12 Jan 2009

Extract from grapes kills lab leukemia cells, proving value of natural compounds

An extract from grape seeds forces laboratory leukemia cells to commit cell suicide, according to researchers from the University of Kentucky.

1 Jan 2009

Cancer is on the increase in Australia

The report shows that the number of new cancer cases diagnosed in Australia each year passed the 100,000 mark for the first time in 2005 and the number of new cases in 2008 is estimated to be over 108,000.

22 Dec 2008

FDA approves Mozobil (plerixafor) for multiple myeloma or non-Hodgkin's lymphomas

The U.S. Food and Drug Administration has approved Mozobil (plerixafor), a drug that helps increase the number of blood stem cells for bone marrow transplantation in patients with certain forms of blood cancer.

18 Dec 2008

Researchers identify how key mutations occur in human lymphomas

Researchers at the Keck School of Medicine of the University of Southern California (USC) have explained how certain key mutations occur in human lymphomas - a process that has, until now, remained a mystery.

12 Dec 2008

Enzyme that mutates antibodies also targets cancer-causing gene

The human immune system is in a perpetual state of self-experimentation. It expertly mutates and shuffles the DNA of its own cells to evolve new defenses against the vast array of microbes that try to invade our bodies.

12 Dec 2008

Trial looks at new treatment for solid cancer tumors and non-Hodgkin's lymphoma

Researchers at The Cancer Institute of New Jersey (CINJ) have opened a clinical trial, which aims to evaluate a new treatment for solid cancer tumors and non-Hodgkin's lymphoma (NHL) in combination with a chemotherapy agent called cyclophosphamide.

12 Dec 2008

Enzyme that mutates antibodies also targets a cancer-causing oncogene

Rockefeller University scientists have discovered that the same enzyme that enables the immune system's defensive creativity is also responsible for a particular genetic malfunction - a translocation of one piece of DNA to the wrong chromosome - that causes Burkitt's lymphoma.

12 Dec 2008

An enzyme that mutates antibodies also targets a cancer-causing oncogene

11 Dec 2008

Pralatrexate shows promise for T-Cell lymphoma

Preliminary results of a pivotal Phase 2 clinical trial of pralatrexate (PDX), a drug that partially works by mimicking folic acid, showed a complete or partial response in 27 percent of patients with recurrent or resistant peripheral T-cell lymphoma (PTCL).

10 Dec 2008